Why the study?
Hypertrophic cardiomyopathy is characterized by phenotypic variability, and this study aimed to evaluate miR-146a as a candidate genetic factor influencing the disease phenotype.
Does the rs2910164 polymorphism in the MIR146A gene and plasma miR-146a-5p levels correlate with the phenotypic features of hypertrophic cardiomyopathy?
Does the rs2910164 polymorphism in the MIR146A gene and plasma miR-146a-5p levels correlate with the phenotypic features of hypertrophic cardiomyopathy?
The rs2910164 SNP in the MIR146A gene and plasma levels of miR-146a-5p are associated with the obstructive phenotype and structural changes in patients with hypertrophic cardiomyopathy.
C allele of rs2910164 may modulate HCM phenotype; leaves open validation as biomarker or therapeutic target.
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the myocardium that is characterized by phenotypic variability among patients. miR-146a is a small non-coding RNA that is well known for its role in inflammation and myocardial hypertrophy. The aim of this study is to evaluate the role of miR-146a as a candidate genetic factor influencing HCM phenotype. In this study, 140 HCM patients and 112 control individuals were genotyped for the rs2910164 single nucleotide polymorphism (SNP) in the MIR146A gene; using this data, the correlation between different genotypes and clinical features of the disease were determined. Additionally, plasma levels of miR-146a-5p were determined in 50 HCM patients and 30 control individuals by using qPCR. The incidence of GC and CC genotypes were significantly lower in HCM patients (odds ratio (OR) = 0.5 [0.3–0.8], p = 0.007). The GC/CC genotypes in the dominant genetic model positively correlated with the presence of left ventricle outflow tract (LVOT) obstruction (OR = 2.3 [1.2–4.7] and p = 0.018), a higher left ventricle mass index (118 ± 47 g/m2 vs 92 ± 42 g/m2 and p = 0.02), and increased left ventricle end-diastolic diameter (4.66 ± 0.64cm vs 4.39 ± 0.7cm and p = 0.026). Atrial fibrillation was significantly higher in patients homozygous for the C allele (OR = 10.6 [2–55], p = 0.003). Interestingly, the plasma levels of miR-146a-5p were significantly increased in HCM patients with LVOT obstruction. Our findings indicate that the C allele of the rs2910164 SNP might be under negative selection in HCM patients. Additionally, plasma levels of miR-146a-5p and GC/CC genotypes are indicative of the obstructive phenotype in HCM patients.
No takes yet. Share an insight, caveat, or question.
Ntelios et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: